Oncopeptides AB (ST:ONCO) — Market Cap & Net Worth
Market Cap & Net Worth: Oncopeptides AB (ONCO)
Oncopeptides AB (ST:ONCO) has a market capitalization of $71.37 Million (Skr663.20 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #20613 globally and #366 in its home market, demonstrating a 4.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncopeptides AB's stock price Skr1.74 by its total outstanding shares 381148118 (381.15 Million). Also see ONCO asset base for a full breakdown of the balance sheet.
Oncopeptides AB Market Cap History: 2017 to 2026
Oncopeptides AB's market capitalization history from 2017 to 2026. Data shows change from $3.28 Billion to $71.37 Million (-28.47% CAGR). Also see cash flow conversion of Oncopeptides AB for how efficiently the company converts equity into cash flow.
Oncopeptides AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncopeptides AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Oncopeptides AB for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.77x
Oncopeptides AB's market cap is 2.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $6.96 Billion | $19.36 Million | -$1.59 Billion | 359.63x | N/A |
| 2021 | $344.55 Million | $118.30 Million | -$1.43 Billion | 2.91x | N/A |
| 2022 | $498.36 Million | $8.36 Million | -$337.95 Million | 59.65x | N/A |
| 2023 | $314.20 Million | $35.22 Million | -$249.11 Million | 8.92x | N/A |
| 2024 | $63.82 Million | $31.65 Million | -$284.61 Million | 2.02x | N/A |
| 2025 | $197.09 Million | $71.12 Million | -$249.59 Million | 2.77x | N/A |
Competitor Companies of ONCO by Market Capitalization
Companies near Oncopeptides AB in the global market cap rankings as of September 19, 2026. Review ONCO tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Oncopeptides AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Oncopeptides AB Historical Marketcap From 2017 to 2026
Between 2017 and today, Oncopeptides AB's market cap moved from $3.28 Billion to $ 71.37 Million, with a yearly change of -28.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr71.37 Million | -63.79% |
| 2025 | Skr197.09 Million | +208.80% |
| 2024 | Skr63.82 Million | -79.69% |
| 2023 | Skr314.20 Million | -36.95% |
| 2022 | Skr498.36 Million | +44.64% |
| 2021 | Skr344.55 Million | -95.05% |
| 2020 | Skr6.96 Billion | +33.73% |
| 2019 | Skr5.21 Billion | -3.42% |
| 2018 | Skr5.39 Billion | +64.25% |
| 2017 | Skr3.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Oncopeptides AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $71.37 Million USD |
| MoneyControl | $71.37 Million USD |
| MarketWatch | $71.37 Million USD |
| marketcap.company | $71.37 Million USD |
| Reuters | $71.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more